Keytruda Qlex, an injectable version of Merck’s cancer immunotherapy, can be administered in minutes compared to the 30 minutes needed to dose the original infused formulation. The FDA approval is based on clinical trial results showing the injectable formulation was comparable to infused Keytruda.
The post Merck’s Injectable Version of Blockbuster Cancer Drug Keytruda Wins FDA Approval appeared first on MedCity News.
